down arrow

iBio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4510337086
USD
1.28
0.24 (23.08%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.031.30

52 Week

0.566.89
Valuation
Technical
Day's Volume

CASH

2.36 M

Shareholding (Mar 2025)

FII

9.34%

Held by 7 FIIs

DII

87.97%

Held by 3 DIIs

Promoter

0.00%

How big is iBio, Inc.?

22-Jun-2025

As of Jun 18, iBio, Inc. has a market capitalization of 13.22 million, classifying it as a Micro Cap company, with net sales of 0.37 million and a net profit of -16.46 million over the latest four quarters. As of Jun 24, the company's shareholder's funds were 21.32 million, and total assets were 28.73 million.

Market Cap: As of Jun 18, iBio, Inc. has a market capitalization of 13.22 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, iBio, Inc. reported net sales of 0.37 million and a net profit of -16.46 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the company's shareholder's funds amounted to 21.32 million, while total assets were reported at 28.73 million.

Read More

What does iBio, Inc. do?

22-Jun-2025

iBio, Inc. is a biotechnology company focused on commercializing technologies and product candidates in the Pharmaceuticals & Biotechnology industry, with a market cap of $13.22 million and a recent net profit of -$5 million. The company has no dividend yield and operates at a loss, reflected in its negative financial metrics.

Overview: <BR>iBio, Inc. is a biotechnology company focused on commercializing its technologies and product candidates within the Pharmaceuticals & Biotechnology industry, and it operates in the micro-cap market.<BR><BR>Financial Snapshot: <BR>- Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>- Market cap: USD 13.22 Million (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: NA (Loss Making) <BR>- Industry P/E: NA <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.30 <BR>- Return on Equity: -144.63% <BR>- Price to Book: 1.16 <BR><BR>Contact Details: <BR>- Address: 600 Madison Ave Ste 1601, NEW YORK NY: 10022-1737 <BR>- Tel: ['1 302 3550650', '1 646 2743580'] <BR>- Fax: 1 302 3561173 <BR>- Website: https://www.ibioinc.com/

Read More

Who are in the management team of iBio, Inc.?

22-Jun-2025

As of March 2022, the management team of iBio, Inc. includes Chairman and CEO Thomas Isett, Interim Secretary and Treasurer Robert Kay, and independent directors Linda Armstrong, Glenn Chang, Seymour Flug, Gen. (Retd.) James Hill, and Alexandra Kropotova. They are responsible for the company's governance and strategic direction.

As of March 2022, the management team of iBio, Inc. includes the following individuals:<BR><BR>- Mr. Thomas Isett: Chairman of the Board, President, Chief Executive Officer<BR>- Mr. Robert Kay: Interim Secretary, Interim Treasurer, Director<BR>- Dr. Linda Armstrong: Independent Director<BR>- Mr. Glenn Chang: Independent Director<BR>- Mr. Seymour Flug: Independent Director<BR>- Gen. (Retd.) James Hill: Independent Director<BR>- Dr. Alexandra Kropotova: Independent Director<BR><BR>These individuals play key roles in the governance and strategic direction of the company.

Read More

Is iBio, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, iBio, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, indicating a solid financial position compared to peers like Moderna and Novavax.

As of 15 October 2023, iBio, Inc. has moved from fair to attractive based on recent evaluations. The company appears to be undervalued at this time. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, indicating a solid financial position relative to its earnings and assets.<BR><BR>In comparison to its peers, Moderna has a price-to-earnings ratio of 18.0, while Novavax stands at 15.0, suggesting that iBio, Inc. is trading at a discount relative to these established companies in the biotech sector. Additionally, iBio's stock performance has outpaced the Sensex recently, reinforcing the notion that it may be undervalued in the current market context.

Read More

Is iBio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, iBio, Inc. is in a mildly bearish trend, with daily moving averages and weekly Dow Theory indicating weakness, despite some mildly bullish signals from MACD and KST, and it has underperformed the S&P 500 with a year-to-date return of -64.49%.

As of 2 September 2025, the technical trend for iBio, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish trend and the weekly Dow Theory showing a bearish signal. While the MACD and KST are mildly bullish on a weekly basis, the overall indicators suggest weakness. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -64.49% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.49

stock-summary
Return on Equity

-123.50%

stock-summary
Price to Book

1.13

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
57.77%
0%
57.77%
6 Months
29.52%
0%
29.52%
1 Year
-51.52%
0%
-51.52%
2 Years
-52.59%
0%
-52.59%
3 Years
-96.24%
0%
-96.24%
4 Years
-99.61%
0%
-99.61%
5 Years
-14.09%
0%
-14.09%

iBio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is iBio, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for iBio, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish trend and the weekly Dow Theory showing a bearish signal. While the MACD and KST are mildly bullish on a weekly basis, the overall indicators suggest weakness. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -64.49% versus the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-24.59%
EBIT Growth (5y)
-7.66%
EBIT to Interest (avg)
-21.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.01%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.43
EV to EBIT
-0.76
EV to EBITDA
-0.82
EV to Capital Employed
1.61
EV to Sales
12.85
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-211.17%
ROE (Latest)
-144.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (2.69%)

Foreign Institutions

Held by 7 Foreign Institutions (9.34%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -6.12% vs -11.36% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-4.60",
          "chgp": "-6.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-4.90",
          "chgp": "-6.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-25,990.00%",
          "val2": "0.00%",
          "chgp": "-2,599.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 47.44% vs 0.68% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.40",
          "val2": "-27.70",
          "chgp": "44.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.40",
          "val2": "-29.30",
          "chgp": "47.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-73,928.90%",
          "val2": "0.00%",
          "chgp": "-7,392.89%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.20
0.00
Operating Profit (PBDIT) excl Other Income
-4.90
-4.60
-6.52%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.20
-4.90
-6.12%
Operating Profit Margin (Excl OI)
-25,990.00%
0.00%
-2,599.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -6.12% vs -11.36% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.20
0.00
Operating Profit (PBDIT) excl Other Income
-15.40
-27.70
44.40%
Interest
0.20
0.10
100.00%
Exceptional Items
0.00
-0.60
100.00%
Consolidate Net Profit
-15.40
-29.30
47.44%
Operating Profit Margin (Excl OI)
-73,928.90%
0.00%
-7,392.89%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs -100.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 47.44% vs 0.68% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About iBio, Inc. stock-summary
stock-summary
iBio, Inc.
Pharmaceuticals & Biotechnology
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
Company Coordinates stock-summary
Company Details
600 Madison Ave Ste 1601 , NEW YORK NY : 10022-1737
stock-summary
Tel: 1 302 35506501 646 2743580
stock-summary
https://www.ibioinc.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."